<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04451668</url>
  </required_header>
  <id_info>
    <org_study_id>CLFT218-1901</org_study_id>
    <nct_id>NCT04451668</nct_id>
  </id_info>
  <brief_title>An Open Label Study of FT218 in Subjects With Narcolepsy</brief_title>
  <acronym>RESTORE</acronym>
  <official_title>Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avadel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avadel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open Label Study to Evaluate Long-Term Safety and Tolerability of a Once Nightly&#xD;
      Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) and the ability to&#xD;
      switch from twice-nightly immediate release sodium oxybate to once-nightly FT218 for the&#xD;
      Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects with Narcolepsy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll subjects with narcolepsy, either NT1 or NT2, who completed the FT218&#xD;
      Phase 3 REST-ON study or eligible subjects with narcolepsy currently receiving a stable dose&#xD;
      of twice nightly sodium oxybate IR or mixed salts oxybate (regardless of whether they&#xD;
      participated in the REST-ON study), or subjects who are naïve to oxybate therapy (i.e.,&#xD;
      FT218, twice nightly sodium oxybate IR or mixed salts oxybate). Following a screening period,&#xD;
      subjects who meet the entry criteria will be enrolled into the study. Subjects who completed&#xD;
      the FT218 Phase 3 REST-ON study will initiate treatment with FT218 at 4.5 g and will follow a&#xD;
      titration schedule up to the highest tolerate dose (up to 9 g), or the dose deemed effective&#xD;
      by the investigator. Subjects previously maintained on twice nightly sodium oxybate IR will&#xD;
      initiate FT218 treatment at a dose equivalent or closest to the total gram dose of&#xD;
      twice-nightly sodium oxybate IR and then titrate up or down, in accord with safety and&#xD;
      effectiveness as determined by the investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label treatment with FT218 (once nightly sodium oxybate extended release)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-related adverse events</measure>
    <time_frame>24 months</time_frame>
    <description>Assess the long-term safety and tolerability of FT218 by the number of participants experiencing treatment-related adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs</measure>
    <time_frame>24 months</time_frame>
    <description>Assess the long-term safety and tolerability of FT218 by the number of participants experiencing clinically significant changes in vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in laboratory test results</measure>
    <time_frame>24 months</time_frame>
    <description>Assess the long-term safety and tolerability of FT218 by the number of participants experiencing clinically significant changes in laboratory test results</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Narcolepsy</condition>
  <condition>Cataplexy</condition>
  <condition>Excessive Daytime Somnolence</condition>
  <condition>Sleep Disorder</condition>
  <condition>Sleep Disturbance</condition>
  <condition>Sleep Wake Disorders</condition>
  <arm_group>
    <arm_group_label>FT218</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once nightly sodium oxybate extended release oral solution (FT218)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FT218</intervention_name>
    <description>once nightly sodium oxybate extended release</description>
    <arm_group_label>FT218</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects receiving a stable doses of twice-nightly sodium oxybate IR or mixed salts&#xD;
             oxybate for at least 4 weeks and are willing to switch to FT218&#xD;
&#xD;
          -  Subjects who completed the CLFT218-1501 REST-ON Study in a compliant manner and for&#xD;
             whom the Investigator determines would receive benefit from treatment with FT218 and&#xD;
             have not started treatment with twice nightly sodium oxybate IR or mixed salts oxybate&#xD;
&#xD;
          -  Are treatment naïve to any oxybate therapy (i.e. FT218, twice nightly sodium oxybate&#xD;
             IR or mixed salts oxybate)&#xD;
&#xD;
          -  Subjects have a diagnosis of narcolepsy, either confirmed prior to the REST-ON study&#xD;
             or as confirmed by the Investigator as defined by the International Classification of&#xD;
             Sleep Disorders 3 criteria (AASM 2014)&#xD;
&#xD;
          -  Willing and able to give written informed consent for study participation. Young&#xD;
             adults (16 and 17 years old) who have not reached the age of majority must be capable&#xD;
             of giving assent in addition to consent from a legally authorized guardian, as&#xD;
             required by local laws and regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects that terminated the CLFT218-1501 REST-ON Study prior to completing Visit 8&#xD;
&#xD;
          -  Any use of the following medications during the study: Anticonvulsants, Clonidine,&#xD;
             Hypnotics, Anxiolytics, Sedating antihistamines, Antipsychotics, Other experimental&#xD;
             medications designed to treat narcolepsy, cataplexy or any other condition, or other&#xD;
             medications with significant sedating effects/CNS depressant effects are prohibited&#xD;
             for REST-ON and naive patients. Patients on twice nightly sodium oxybate IR on&#xD;
             medications in classes listed above may be eligible for enrollment if the subject has&#xD;
             been on a stable dose of the prohibited medication in combination with a stable dose&#xD;
             of twice nightly sodium oxybate or mixed salts oxybate for at least three months and&#xD;
             has demonstrated no AEs, intolerance, or interactions AND is approved to participate&#xD;
             by the Medical Monitor. Sedative hypnotics are prohibited regardless.)&#xD;
&#xD;
          -  A diagnosis of sleep apnea where AHI is ≥15 and/or current use of CPAP or other&#xD;
             devices for sleep apnea.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sleep Disorders Center of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wes Booth</last_name>
      <phone>205-599-1020</phone>
      <phone_ext>122</phone_ext>
      <email>wbooth@sleepalabama.com</email>
    </contact>
    <investigator>
      <last_name>Robert Doekel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Sleep Medicine</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Byrd</last_name>
      <phone>803-251-3093</phone>
      <email>Heather.Byrd@bogansleep.com</email>
    </contact>
    <investigator>
      <last_name>Clete Kushida</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SDS Clinical Trials</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Withrow</last_name>
      <phone>714-834-1565</phone>
      <email>Jane@sdsclinicaltrials.com</email>
    </contact>
    <contact_backup>
      <last_name>Johnny Salvador</last_name>
      <phone>714-834-1565</phone>
      <email>Johnny@sdsclinicaltrials.com</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Schreiber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alpine Clinical Research Center</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Lewis</last_name>
      <phone>303-443-7229</phone>
      <phone_ext>105</phone_ext>
      <email>chris@alpineresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Mary Ann St. John</last_name>
      <phone>303-443-7229</phone>
      <phone_ext>103</phone_ext>
      <email>maryann@alpineresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>John Harsh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delta Waves, Inc.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80918</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joe Schulz</last_name>
      <phone>719-262-9283</phone>
      <phone_ext>109</phone_ext>
      <email>joe@deltawaves.org</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Bryant</last_name>
      <phone>719-262-9283</phone>
      <phone_ext>109</phone_ext>
      <email>sarah@deltawaves.org</email>
    </contact_backup>
    <investigator>
      <last_name>Samuel Scheuller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pulmonary Disease Specialists, PA</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Goodwin</last_name>
      <phone>407-624-4831</phone>
      <email>CGoodwin@PDS-CFSC.com</email>
    </contact>
    <contact_backup>
      <last_name>James Youngue</last_name>
      <phone>407-624-4831</phone>
      <email>jyongue@pds-cfsc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas O'Brien</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FL Pediatric Research Institute</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Patenaude</last_name>
      <phone>407-898-2767</phone>
      <email>heidi@ajayihealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Akinyemi Ajayi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NeuroTrials Research Inc</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melody Morgan</last_name>
      <phone>404-851-9934</phone>
      <email>mmorgan@neurotrials.com</email>
    </contact>
    <contact_backup>
      <last_name>Arnetria Cobb Dancy</last_name>
      <phone>404-851-9934</phone>
      <email>acdancy@neurotrials.com</email>
    </contact_backup>
    <investigator>
      <last_name>Russell Rosenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SleepCare Research Institute, Inc. d/b/a Clinical Research Institute</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverley Jenkins</last_name>
      <phone>678-782-5358</phone>
      <email>bjenkins@clinicalresearchinstitute.us</email>
    </contact>
    <contact_backup>
      <last_name>Zaneta Tatum</last_name>
      <phone>678-782-5358</phone>
      <email>ztatum@clinicalresearchinstitute.us</email>
    </contact_backup>
    <investigator>
      <last_name>Phillip Nowlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Neurological</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mindy Schroeder</last_name>
      <phone>260-436-3991</phone>
      <phone_ext>2185</phone_ext>
      <email>mglass@fwnc.com</email>
    </contact>
    <investigator>
      <last_name>James Stevens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helene A. Emsellem, MD PC</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Menkis</last_name>
      <phone>301-654-5665</phone>
      <email>monica@sleepdoc.com</email>
    </contact>
    <investigator>
      <last_name>Helene Emsellem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital - Sleep Medicine and Research Center</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Griffin</last_name>
      <phone>314-205-6475</phone>
      <email>Kara.Griffin@stlukes-stl.com</email>
    </contact>
    <investigator>
      <last_name>Paula Schweitzer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Sleep-Wake Disorders Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Figuera Losada</last_name>
      <phone>718-920-2880</phone>
      <email>mfiguera@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Monica Petrisko</last_name>
      <phone>718-920-2880</phone>
      <email>mpetrisk@montefiore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Thorpy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Respiratory and Sleep Medicine</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Kurniawan</last_name>
      <phone>704-248-0000</phone>
      <phone_ext>111</phone_ext>
      <email>felix@arsmnc.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Stern</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sleep Management Institute Intrepid Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Waddell</last_name>
      <phone>513-977-8891</phone>
      <email>PWaddell@intrepidresearch.md</email>
    </contact>
    <contact_backup>
      <last_name>Erica Eves</last_name>
      <phone>513-977-8888</phone>
      <phone_ext>891</phone_ext>
      <email>eeves@intrepidresearch.md</email>
    </contact_backup>
    <investigator>
      <last_name>Bruce Corser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Denallo</last_name>
      <phone>216-286-7453</phone>
      <email>erica.denallo@uhhospitals.org</email>
    </contact>
    <contact_backup>
      <last_name>Ryan Kneram</last_name>
      <phone>216-286-0259</phone>
      <email>Ryan.Kneram@UHhospitals.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sally Ibrahim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Sleep Medicine Institute</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Datema</last_name>
      <phone>614-766-0773</phone>
      <phone_ext>111</phone_ext>
      <email>kathy@sleepmedicine.com</email>
    </contact>
    <investigator>
      <last_name>Asim Roy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brian Abaluck Sleep Medicine</name>
      <address>
        <city>Malvern</city>
        <state>Pennsylvania</state>
        <zip>19355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Quinn</last_name>
      <phone>610-608-2977</phone>
      <email>Anna@BrianAbaluck.com</email>
    </contact>
    <investigator>
      <last_name>Brian Abaluck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bogan Sleep Consultants, LLC</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Boyer</last_name>
      <phone>803-251-3039</phone>
      <email>kim.boyer@bogansleep.com</email>
    </contact>
    <investigator>
      <last_name>Richard Bogan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Neurology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Ford</last_name>
      <phone>512-380-9925</phone>
      <phone_ext>219</phone_ext>
      <email>kevinf@fstrials.com</email>
    </contact>
    <investigator>
      <last_name>Johnathan Hudson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sleep Therapy &amp; Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-4849</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Rafati</last_name>
      <phone>210-614-6000</phone>
      <email>rafati.sue@sleeptrc.com</email>
    </contact>
    <contact_backup>
      <last_name>Debra Galvan</last_name>
      <email>galvan.debra@sleeptrc.com</email>
    </contact_backup>
    <investigator>
      <last_name>James Andry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TPMG Clinical Research Williamsburg</name>
      <address>
        <city>Williamsburg</city>
        <state>Virginia</state>
        <zip>23188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Bloch</last_name>
      <phone>757-707-3503</phone>
      <email>dawn.bloch1@tpmgpc.com</email>
    </contact>
    <investigator>
      <last_name>Richard Parisi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Perry Sound Health Center</name>
      <address>
        <city>Parry Sound</city>
        <state>Ontario</state>
        <zip>P2A 3A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naheed Hossain</last_name>
      <phone>647-291-5800</phone>
      <email>naheedkhossain@jodhatishon.com</email>
    </contact>
    <contact_backup>
      <last_name>Durdana Akhter</last_name>
      <phone>647-575-5371</phone>
      <email>durdanabd@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Colin Shapiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jodha Tishon Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 3A3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naheed Hossain</last_name>
      <phone>647-291-5800</phone>
      <email>naheedkhossain@jodhatishon.com</email>
    </contact>
    <contact_backup>
      <last_name>Durdana Akhter</last_name>
      <phone>647-291-5800</phone>
      <email>durdanabd@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Colin Shapiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 23, 2020</study_first_submitted>
  <study_first_submitted_qc>June 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2020</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Narcolepsy</mesh_term>
    <mesh_term>Cataplexy</mesh_term>
    <mesh_term>Disorders of Excessive Somnolence</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Sleepiness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

